Formulation Development
Septerna & Novo Nordisk to Collaborate on Oral Small Molecule Medicines for Obesity & Other Cardiometabolic Diseases
Septerna, Inc. and Novo Nordisk recently announced an exclusive global collaboration and license agreement to discover, develop, and commercialize oral small molecule medicines for obesity,…
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager for Autoimmune Disease
IN8bio, Inc. recently announced new preclinical data from its INB-619 program at the 2025 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The data…
Veranova Appoints Elizabeth Rebeil as Global Vice President of Supply Chain & Operational Excellence
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors, is pleased…
Polyrizon Targets $3.15B Epilepsy Market With Preclinical Studies for Innovative Rescue Treatment
Polyrizon Ltd. recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using…
HCW Biologics Announces Positive Results of Studies of Proprietary Compound & Availability for Commercialization
HCW Biologics Inc. recently announced presentation of studies showing that its proprietary fusion protein, HCW9206, provides a new pathway for generating chimeric T-cell receptor -…
Oragenics Announces Approval to Initiate Phase 2 Concussion Drug Trial
Oragenics, Inc. recently announced it has received approval from the Human Research Ethics Committee (HREC) in Australia to initiate its Phase 2 clinical trial evaluating…
Alzamend Neuro Initiates First Phase 2 Trial of AL001 “Lithium in Brain” Study
Alzamend Neuro, Inc. recently today announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy…
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
Invivyd, Inc. recently announced it has initiated a discovery program for a measles monoclonal antibody (mAb). Multiple healthcare providers (HCPs) who are treating active measles…
ABLi Therapeutics Launches With a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
ABLi Therapeutics recently launched with the mission of developing its lead product candidate, Risvodetinib (ABLi-148009), as a potential disease-modifying therapy for Parkinson’s and Parkinson’s-related diseases…
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated With Intranasal Foralumab
Tiziana Life Sciences, Ltd. recently announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from…
Colorcon & ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical & Nutraceutical Industries
Colorcon recently announced an exclusive partnership with ASHA Cellulose, a leading provider of organo-soluble Ethyl cellulose polymers widely used in the pharmaceutical and dietary supplement…
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Toward Anti-Fibrotic Effect of GRI-0621 in First 12 Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis
GRI Bio, Inc. recently reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”). Additionally, management…
Amneal & Apiject to Expand Sterile & Blow-Fill-Seal Capabilities for Advanced Pharmaceutical Manufacturing in the US
Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. recently announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s Brookhaven, NY…
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Conduit Pharmaceuticals Inc. recently announced the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase (MPO)…
SPECIAL FEATURE - PFS & Parenteral Delivery: Innovation Is Focused on Patient-Centric, Smart & Sustainable Solutions
Contributor Cindy H. Dubin speaks with several innovating companies to discuss trends in PFS as well as advancements in autoinjectors and innovations in parenteral delivery.
TRANSDERMAL DELIVERY - SkinJect’s Doxorubicin-Loaded Dissolvable Microneedle Array (D-MNA): A Revolutionary Approach to Transdermal Drug Delivery
Raza Bokhari, MD, Edward Brennan, MD, FACS, and Madison Weisz, MS, explore the D-MNA treatment, highlighting its drug delivery mechanisms, advantages over traditional treatments, and clinical potential.
Aenova Launches Aenovation(TM) Program to Accelerate Pharmaceutical Development
Aenova, a leading contract development and manufacturing organization (CDMO) in the global pharmaceutical supply chain, recently announced the launch of its innovative Aenovation(TM) program. This…
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
FORMULATION FORUM - Self-Emulsifying Drug Delivery Systems for Improving Oral Bioavailability of Drugs
Jim Huang, PhD, and Shaukat Ali, PhD, say as more NCEs continue to be discovered with less options to find the appropriate excipients and solubilizers for Class II and IV drugs, the pharma industry has begun to evaluate liquid SEDDS for expediting drugs to market.
EXECUTIVE INTERVIEW - Botanical Solution Inc.: Launching a Revolution in Economical & Environmentally Sustainable QS-21 Vaccine Adjuvant Production
Gastón Salinas, CEO of Botanical Solution Inc., discusses his company’s transition from agriculture to pharmaceuticals, addressing the global shortage of QS-21, and developing the QS-21 gold standard vaccine.
